Positive Results Announced from Clinical Trial of BAF-312 (Siponimod) in Secondary Progressive MS


  • According to a company press release, in a 60-month, phase III clinical trial involving 1,651 people with secondary progressive MS, the experimental oral therapy siponimod (BAF312, Novartis Pharmaceuticals AG) met its primary endpoint of reducing the risk of disability progression compared with inactive placebo.
  • These results were announced in an August 25, 2016 press release from Novartis. Further results are being presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in September.
Background: Siponimod (BAF312) is an experimental immune…

Favicon of www.nationalmssociety.org da : www.nationalmssociety.org

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati